A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated a
s oral antihyperglycemic agents in the obese insulin resistant db/db and ob
/ob mouse - the two models for Type 2 diabetes mellitus. The majority of th
e prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-dion
es normalized plasma glucose levels at the 100 mg kg(-1) oral dose in the d
b/db diabetic mouse model, and several amongst them reduced the glucose lev
els at the 20 mg kg(-1) oral dose. The most potent compounds in the db/db m
ouse model were also active in the ob/ob mouse model normalizing the plasma
glucose levels at the 20 mg kg(-1) oral dose. The trifluoromethoxy analog
32 was the most active compound of the series, reducing significantly the p
lasma glucose levels at the 5 mg kg(-1) oral dose. Oxadiazole-tailed 1,2,4-
oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diab
etic mouse models normalizing plasma glucose levels at the 100 mg kg(-1) or
al dose. (C) 2001 Editions scientifiques et medicales Elsevier SAS.